Castelein Caley's Disposal of Tourmaline Bio, Inc. Shares and Stock Options

On October 28, 2025, Castelein Caley, a director of Tourmaline Bio, Inc., disposed of 515,997 shares of common stock directly and 431,939 shares indirectly through KVP Capital, LP. Additionally, Caley disposed of 36,800 employee stock options (right to buy) with exercise prices ranging from $9.46 to $18.73. These transactions were part of a cash tender offer completed by Torino Merger Sub Inc., an indirect wholly owned subsidiary of Novartis AG, to acquire all shares of Tourmaline Bio, Inc. for $48.00 per share. The stock options were automatically canceled and converted into cash based on the difference between the merger consideration and the exercise price.